PHARMACEUTICAL COMPOSITION COMPRISING NOVEL SD911 COMPOUND AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF TRANSPLANT REJECTION

• Main Authors: CHO, Mi La, YANG, Chul Woo, SHIN, Yoo Jin, LIM, Sun Woo, LEE, A Ram, SHIN, Dongyun, LEE, Seon Yeong
• Format: Patent
• Language: English; French; Korean
• Published: 20.10.2022
• Subjects: FOODS OR FOODSTUFFS; FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BYSUBCLASSES A23B - A23J; HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OFNUTRITIVE QUALITIES, PHYSICAL TREATMENT; THEIR TREATMENT, NOT COVERED BY OTHER CLASSES

The present invention relates to a pharmaceutical composition comprising a novel compound as an active ingredient for prevention or treatment of transplant rejection. The novel compound SD911 of the present invention was identified to repress the migration of immune cells, increase the engraftment and viability of a grafted tissue, and regulate immune cells. In addition, it was found in a kidney transplantation model that the compound restrained human PBMC from suppressing the engraftment and damaging renal tissues and downregulated the expression of the inflammatory cytokine IL-17, with the consequent effective prevention and treatment of transplant rejection. La présente invention concerne une composition pharmaceutique comprenant un nouveau composé utilisé en tant que principe actif pour la prévention ou le traitement du rejet de greffe. Selon la présente invention, le nouveau composé SD911 a été identifié pour supprimer la migration de cellules immunitaires, pour augmenter la prise de greffe et la viabilité d'un tissu greffé et pout réguler des cellules immunitaires. En outre, il a été découvert dans un modèle de transplantation de rein que le composé a empêché les CMSP humaines de supprimer la prise de greffe et d'endommager les tissus rénaux, et a régulé à la baisse l'expression de la cytokine inflammatoire IL-17, permettant ainsi la prévention et le traitement efficaces du rejet de greffe. 본 발명은, 신규한 화합물을 유효성분으로 포함하는, 이식 거부 반응의 예방 또는 치료용 약학적 조성물에 관한 것으로서, 본 발명의 신규한 화합물인 SD911이 면역 세포의 이동을 억제하고, 이식된 조직의 생착 및 생존율을 증가시키고, 면역 세포를 조절하는 것을 확인하였다. 또한, 신장 이식 모델에서, human PBMC의 생착 억제 및 신장 조직 손상을 억제하고, 염증성 사이토카인인 IL-17의 발현을 억제하는 것을 확인하여, 이식 거부 반응에 효과가 있는 것을 확인하였다.